Skip to content
Dr. Reddy’s
-
Dr. Reddy’s expands access to immunotherapy for rare nasopharyngeal cancer in South Africa
The U.S. National Cancer Institute estimates that more than 500 rare cancers exist, many of which receive limited public attention despite their significant impact on patients and families.
-
Dr. Reddy’s ends distribution agreement with Novartis India due to ownership change
Under the four-year agreement, Novartis India had granted Dr Reddy’s an exclusive and non-transferable right to promote, distribute and sell certain products in the Indian market.
-
Dr. Reddy’s halts generic semaglutide supply due to API quality issues
The setback comes at a crucial time as competition intensifies in the fast-growing market for lower-cost versions of Novo Nordisk’s blockbuster diabetes and obesity medicine.